A NEW comprehensive review examining the economic impact of autoimmune CNS disease multiple sclerosis (MS) in Australia reveals it is costing the country a whopping $1.75 billion annually.
Lost wages now account for just one third (32%) of the total economic burden compared to almost half (49%) of the burden seven years ago, the report said.
The high cost of new treatments and a 20% increase in patient numbers are also impacting.
The 'Health Economic Impact of Multiple Sclerosis in Australia 2017' report, commissioned by MS Research Australia and supported by a Merck Australia research grant, is being launched by Federal Treasurer Scott Morrison at Parliament House today.
The above article was sent to subscribers in Pharmacy Daily's issue from 22 Aug 18
To see the full newsletter, see the embedded issue below or CLICK HERE to download Pharmacy Daily from 22 Aug 18
